Compare FOXX & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FOXX | LSTA |
|---|---|---|
| Founded | 2017 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Misc Health and Biotechnology Services |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.3M | 15.9M |
| IPO Year | 2025 | 2000 |
| Metric | FOXX | LSTA |
|---|---|---|
| Price | $1.40 | $1.20 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 8.9K | ★ 108.7K |
| Earning Date | 11-24-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.42 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $52,584,432.00 | $35,283,868.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 56.90 |
| 52 Week Low | $1.28 | $0.96 |
| 52 Week High | $7.90 | $5.07 |
| Indicator | FOXX | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 21.73 | 56.44 |
| Support Level | N/A | $1.23 |
| Resistance Level | $2.77 | $1.28 |
| Average True Range (ATR) | 0.19 | 0.12 |
| MACD | -0.05 | 0.04 |
| Stochastic Oscillator | 3.03 | 56.18 |
Foxx Development Holdings Inc is a consumer electronics and integrated Internet-of-Things (IoT) solution company catering to both retail and institutional clients. With robust research and development capabilities and a strategic commitment to cultivating long-term partnerships with mobile network operators, distributors, and suppliers. Its products include tablets, smartphones, wearables, and other high-quality communication terminals. The company's current revenue stream is derived from the sales of tablets and smartphones.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.